Markus Schick

Company: AstraZeneca

Job title: Director & Head of Computational Pathology & Biomarker Development

Seminars:

Computational Pathology to Guide Patient Selection for ADCs: Discovery of a Novel TROP2 NMR Biomarker for Predicting Clinical Outcomes 4:30 pm

Computational pathology for revolutionizing the development and delivery of accurate biomarker, tailored to the drug’s mechanism of action Development of Quantitative Continuous Scoring (QCS) – an AI-based solution that allows interrogation of complex target and tumor biology Utilizing the novel computational pathology-based TROP2 NMR biomarker to predict clinical outcomes for Dato-DXd in NSCLCRead more

day: Scientific Program Day One PM